Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OH2 vs regorafenib in colorectal cancer liver metastases
CTR20222722Phase 2Terminated
- Sponsor
- Wuhan Binhui Biopharmaceutical Co., Ltd.
- Start
- Oct 2022
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of OH2 in colorectal cancer (CRC) (2 arms), sponsored by Wuhan Binhui Biopharmaceutical Co., Ltd. Primary endpoint: Overall survival. Started Oct 2022; status: terminated.
02
Drugs
OH2
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20222722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222722.